HLA-C and cancer: A poor responsiveness to immunotherapy (e.g., ICIs) results from a number of factors, including the loss of tumor antigen or MHC expression in cancer cells, immunosuppressive cells, and cytokines in the tumor microenvironment, a lack of pre-existing tumor-reactive T cells, or T cell exhaustion, which collectively contribute to an immunologically ‘cold’ tumor.